资源不足人群胰腺腺癌辅助治疗延迟与生存分析
基于美国国家癌症数据库2006-2017年25008例非转移性胰腺腺癌根治术后接受辅助化疗的患者,分析延迟辅助化疗的相关因素及其对生存的影响。结果显示仅73.3%患者及时启动辅助化疗,年龄、种族、合并症、收入与保险是障碍因素,延迟辅助化疗与资源不足人群更差生存相关。
要点
- 仅73.3%胰腺腺癌患者术后12周内启动辅助化疗。
- 高龄、非西班牙裔黑人、合并症多、30天再入院及Whipple手术与延迟辅助化疗相关。
- 高收入、私人保险、Medicare及新辅助治疗与及时辅助化疗相关。
核心结论
- 胰腺腺癌术后及时辅助化疗仅73.3%达成,多社会经济学与临床因素构成障碍。
- 延迟辅助化疗与资源不足人群(非西班牙裔黑人和低教育水平社区患者)更差总生存相关。
研究设计与样本
- 回顾性队列研究,数据来自美国国家癌症数据库2006-2017年。
- 纳入25008例非转移性胰腺腺癌接受根治性切除后辅助化疗的患者。
主要发现
- 及时辅助化疗比例随分期升高:1期67.9%,2期75.8%,3期89.2%(P < .001)。
- 多因素分析显示高龄(OR 1.02,95%CI 1.02-1.03)、非西班牙裔黑人(OR 1.25,95%CI 1.11-1.41)、合并症评分增加(OR 1.18,95%CI 1.12-1.23)、30天再入院(OR 1.45,95%CI 1.28-1.63)、Whipple手术(OR 1.30,95%CI 1.16-1.44)与延迟辅助化疗相关。
- 最高社区收入四分位(OR 0.84,95%CI 0.73-0.97)、私人保险(OR 0.59,95%CI 0.46-0.76)、Medicare(OR 0.68,95%CI 0.52-0.88)及接受新辅助治疗(OR 0.05,95%CI 0.04-0.06)与及时辅助化疗相关。
- 非西班牙裔黑人和社区教育水平最低的患者中,延迟辅助化疗者总生存更差。
关键数值与推荐
- 美国国家综合癌症网络(NCCN)推荐胰腺腺癌术后12周内启动辅助化疗。
- 及时辅助化疗定义为术后12周内开始辅助化疗。
临床怎么用
- 对高龄、非西班牙裔黑人、合并症多、Whipple术后或30天再入院患者应警惕辅助化疗延迟风险。
- 应关注低收入、无私人保险或Medicare等资源不足人群,制定干预措施促进及时辅助化疗。
局限性
- 回顾性数据库研究可能存在未测量混杂因素。
- 研究仅纳入接受辅助化疗的患者,未涵盖未接受化疗者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The initiation of adjuvant chemotherapy for pancreatic adenocarcinoma within 12 weeks after surgery is recommended by the National Comprehensive Cancer Network. This study seeks to identify factors associated with delayed adjuvant chemotherapy and whether delays impact survival in under-resourced populations. METHODS: Patients with nonmetastatic pancreatic adenocarcinoma who received a definitive resection followed by adjuvant chemotherapy between 2006 and 2017 were queried from the National Cancer Database. Multivariate logistic regression models were constructed to determine the relationship between socioeconomic/clinical variables and delayed adjuvant chemotherapy. Kaplan Meier curves compared survival between under-resourced patients receiving delayed versus timely adjuvant chemotherapy. RESULTS: Among 25,008 patients, timely adjuvant chemotherapy varied by stage (stage 1: 67.9% vs stage 2: 75.8% vs stage 3: 89.2%; P < .001). Older age (odds ratio 1.02, 95% confidence interval 1.02-1.03; P < .001), Non-Hispanic Black race (odds ratio 1.25, 95% confidence interval 1.11-1.41; P < .001), increasing comorbidity score (odds ratio 1.18, 95% confidence interval 1.12-1.23; P < .001), 30-day readmission (odds ratio 1.45, 95% confidence interval 1.28-1.63; P < .001), and undergoing a Whipple (odds ratio 1.30, 95% confidence interval 1.16-1.44; P < .001) were associated with delayed adjuvant chemotherapy. Conversely, the highest neighborhood median income quartile (odds ratio 0.84, 95% confidence interval 0.73-0.97; P = .021), private insurance (odds ratio 0.59, 95% confidence interval 0.46-0.76; P < .001), Medicare (odds ratio 0.68, 95% confidence interval 0.52-0.88; P = .003), and receipt of neoadjuvant therapy (odds ratio 0.05, 95% confidence interval 0.04-0.06; P < .001) were associated with timely adjuvant chemotherapy. Non-Hispanic Black patients and patients with the lowest neighborhood education had worse overall survival when receiving delayed versus timely adjuvant chemotherapy. CONCLUSION: Timely adjuvant chemotherapy for pancreatic adenocarcinoma was only achieved in 73.3% of patients. Age, race, comorbidities, median income, and insurance were identified as barriers. Delayed adjuvant chemotherapy was associated with worse survival among under-resourced populations.
引用
- Hamad A, Eskander MF, Shen C, et al. In search of lost time: Delays in adjuvant therapy for pancreatic adenocarcinoma among under-resourced patient populations. Surgery. 2022. PMID: 35595567. doi:10.1016/j.surg.2022.04.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。